Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)

Historic EBITDA Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' EBITDA Margin rose 31669800.0% to 65.61% in Q2 2024 from the same period last year, while for Dec 2024 it was 18.89%, marking a year-over-year increase of 39263500.0%. This contributed to the annual value of 11.82% for FY2024, which is 34346600.0% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported EBITDA Margin of 65.61% as of Q2 2024, which was up 31669800.0% from 3213.78% recorded in Q4 2023.
  • In the past 5 years, Fulcrum Therapeutics' EBITDA Margin registered a high of 65.61% during Q2 2024, and its lowest value of 9471.19% during Q1 2023.
  • In the last 5 years, Fulcrum Therapeutics' EBITDA Margin had a median value of 1028.79% in 2020 and averaged 2041.4%.
  • Per our database at Business Quant, Fulcrum Therapeutics' EBITDA Margin plummeted by -84441400bps in 2023 and then skyrocketed by 31669800bps in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' EBITDA Margin stood at 420.19% in 2020, then decreased by -12bps to 470.42% in 2021, then crashed by -768bps to 4083.65% in 2022, then rose by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
  • Its EBITDA Margin stands at 65.61% for Q2 2024, versus 3213.78% for Q4 2023 and 3615.28% for Q3 2023.